title: Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: J K
authors.initials: JK
authors.lastname: Winkler
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schneiderbauer
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Bender
authors.affiliation: National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Department of Diagnostic Radiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Sedlaczek
authors.affiliation: National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Department of Translational Oncology, Heidelberg, Germany.|Section for Personalized Oncology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Fröhling
authors.affiliation: Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Penzel
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Enk
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: J C
authors.initials: JC
authors.lastname: Hassel
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004428:Ear Neoplasms / Q000188:drug therapy; D005153:Facial Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab